Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis

Katano, Mitsuo; Nakamura, Minoru; Matsuo, Tatsuya; Iyama, Akihiro; Hisatsugu, Takeharu

doi:10.1007/bf00311527

Cited by 35 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We did not change our previous conclusion that no guideline was possible because of insufficient evidence. The panel concluded that no guideline could be provided for or against the use of subcutaneous G-CSF for the prevention of mucositis in patients treated with CT since studies reported conflicting results [48,49]. Crawford et al [50] reported a beneficial effect, whereas a randomized controlled trial by Patte et al [51] found that G-CSF was not effective to prevent mucositis in this setting (Table 1).…”

Section: Granulocyte Colony-stimulating Factormentioning

confidence: 99%

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Raber-Durlacher

Bültzingslöwen²,

Logan

et al. 2012

Support Care Cancer

113

View full text Add to dashboard Cite

Purpose The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Care Cancer (2013) 21:343-355 DOI 10.1007/s00520-012-1594 following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional welldesigned research is needed on other cytokine and growth factor interventions and in other cancer treatment settings. Methods

show abstract

Section: Granulocyte Colony-stimulating Factormentioning

confidence: 99%

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Raber-Durlacher

Bültzingslöwen²,

Logan

et al. 2012

Support Care Cancer

113

View full text Add to dashboard Cite

show abstract

“…Laboratory studies have shown however, that G-/GM-CSF influence proliferation and migration of non-haematopoietic cells, including endothelial cells 118 and keratinocytes, 119 suggesting that they may act as regulatory signals outside the haematopoietic system. Clinical studies using subcutaneous G-CSF or GM-CSF have shown a beneficial effect on oral mucositis 110,[120][121][122][123][124][125][126] (Table 3). In addition to the amelioration of severe and long-lasting neutropenia, systemic G-CSF or GM-CSF activates neutrophil migration, chemotaxis, phagocytosis and cytotoxicity.…”

Section: G-/gm-csfmentioning

confidence: 99%

Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis – are there new strategies?

Karthaus

Rosenthal

Ganser

1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy. Oral complications may lead to dose reduction or delay in further cancer treatment. Mucositis can be caused directly by cytotoxic effects and indirectly by sustained neutropenia after cytostatic therapy. An impaired mucosal barrier predisposes to life-threatening septic complications during aplasia. The prevalence of an oral focus in febrile neutropenia has been reported in up to 30% of cases and also reduces quality of life. The basic strategies aim at pain relief and prevention of bacterial and fungal infectious complications. However, no effective causal prophylaxis or treatment of oral mucositis is widely accepted. The introduction of cytokines, eg granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) for oral mucositis may be particularly effective and offer a new and hopeful approach. At present, the optimal growth factor, best schedule, effective dosage and best mode of application is not known.

show abstract

“…There was a significant reduction in both grade 3 and 4 mucositis and infection in the GM-CSF-treated arm (Nemunaitis et al, 1995). A Japanese study (Katano et al, 1995) of only 14 patients receiving intra-arterial doxorubicin with or without G-CSF suggested that oral mucositis secondary to doxorubicin can be reduced or prevented by this cytokine.…”

Section: Granulocyte and Granulocyte Macrophage Colony-stimulating Famentioning

confidence: 99%

Treatment-induced mucositis: an old problem with new remedies

Symonds

1998

Br J Cancer

View full text Add to dashboard Cite

Summary Mucositis may be a painful, debilitating, dose-limiting side-effect of both chemotherapy and radiotherapy for which there is no widely accepted prophylaxis or effective treatment. The basis of management is pain relief, prevention of dehydration and adequate nutrition. When tested vigorously, most antiseptic mouthwashes and anti-ulcer agents are ineffective. Simple mechanical cleansing by saline is the most effective traditional measure. A variety of new agents are effective. Granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) act outwith the haemopoeitic system and can reduce mucositis, but the best schedule, dosage and method of administration is not known or which is the best growth factor to prevent this side-effect. A placebo-controlled randomized trial of antibiotic pastilles has shown a significant reduction in mucositis and weight loss during radiotherapy for head and neck cancer. Another method to reduce radiation effects in normal tissue is to stimulate cells to divide before radiotherapy by silver nitrate or interleukin 1. These methods may be particularly effective when given along with hyperfractionated radiation treatment such as CHART.

show abstract

Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis

Cited by 35 publications

References 27 publications

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis – are there new strategies?

Treatment-induced mucositis: an old problem with new remedies

Contact Info

Product

Resources

About